Tumor-invading protein delivers therapy straight to the brain, study finds

Sylvester opens Griffin Cancer Research Building

Sylvester Comprehensive Cancer Center has announced the opening of the Kenneth C. Griffin Cancer Research Building. The building has doubled Sylvester’s research footprint, breaking down barriers between scientific research and patient care.

February 06, 2026

Vol.52 No.05

Clinical Roundup

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer.

January 23, 2026

Vol.52 No.03

In Brief

SU2C + CRUK secure $3M for gastric cancer research

Stand Up To Cancer and Cancer Research UK secured $3 million in new support for a “dream team” focused on stopping gastric cancer in its earliest stages.

January 16, 2026

Vol.52 No.02

Drugs & Targets

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

Verana Health and COTA Inc. are merging with the aim of providing data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care.

January 16, 2026

Vol.52 No.02

Cancer Policy

Journal retracts decades-old study that determined glyphosate, widely used herbicide, as safe

Regulatory Toxicology and Pharmacology has retracted a literature review published in 2000 that concluded that glyphosate, a common herbicide used in agriculture and found in products such as Roundup, “does not pose a health risk to humans.”

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber Cancer Institute has agreed to pay $15 million to the U.S. government in a settlement to resolve allegations that, between 2014 and 2024, Dana-Farber violated the False Claims Act by “using fraudulent images in grant applications and research articles to induce the NIH to pay millions of dollars to support research at Dana-Farber.”

December 19, 2025

Vol.51 No.46

By Jacquelyn Cobb